OKYO PHARMA LTD (OKYO)
GG00BMFG5F62 - Common Stock
OKYO PHARMA LTD
NASDAQ:OKYO (1/14/2025, 8:00:02 PM)
After market: 1.094 +0.06 (+6%)1.0321
+0 (+0.2%)
Company Profile
OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. The firm is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. Its research program is focused on a novel G Protein-Coupled Receptor (GPCR). The firm is developing OK-101, its lead preclinical product candidate, for the treatment of DED. OK-101 is focused on keratoconjunctivitis sicca, commonly referred to as DED, which is a multifactorial disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. The firm also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. The company is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.
Company Info
OKYO PHARMA LTD
Floor 4, 14/15 Conduit St
London
P: 442074952379
Employees: 8
Website: https://okyopharma.com/
OKYO News
2 months ago - OKYO Pharma LTDOKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference2 months ago - ACCESSWIREMUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV3 months ago - OKYO Pharma LTDOKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference3 months ago - OKYO Pharma LTDOKYO Pharma to Present at International Tear Film and Ocular Surface Society ConferenceLONDON and NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...
3 months ago - OKYO Pharma LTDOKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain3 months ago - OKYO Pharma LTDOKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal PainOK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain (NCP) in a clinical trialThe Phase 2 trial is...
OKYO Twits
Here you can normally see the latest stock twits on OKYO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
